hydroxychloroquine has been researched along with Lyme Disease in 10 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Lyme Disease: An infectious disease caused by a spirochete, BORRELIA BURGDORFERI, which is transmitted chiefly by Ixodes dammini (see IXODES) and pacificus ticks in the United States and Ixodes ricinis (see IXODES) in Europe. It is a disease with early and late cutaneous manifestations plus involvement of the nervous system, heart, eye, and joints in variable combinations. The disease was formerly known as Lyme arthritis and first discovered at Old Lyme, Connecticut.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 2-week treatment with ceftriaxone followed by a 12-week regimen of doxycycline or clarithromycin/hydroxychloroquine did not lead to better cognitive performance compared to a 2-week regimen of ceftriaxone in patients with Lyme disease-attributed persistent symptoms." | 5.30 | Effect of prolonged antibiotic treatment on cognition in patients with Lyme borreliosis. ( Berende, A; Evers, AWM; Kessels, RPC; Kullberg, BJ; Ter Hofstede, HJM; van Middendorp, H; Vogelaar, ML; Vos, FJ, 2019) |
| "In a randomized, double-blind, placebo-controlled trial conducted in Europe, we assigned patients with persistent symptoms attributed to Lyme disease--either related temporally to proven Lyme disease or accompanied by a positive IgG or IgM immunoblot assay for Borrelia burgdorferi--to receive a 12-week oral course of doxycycline, clarithromycin plus hydroxychloroquine, or placebo." | 5.22 | Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease. ( Berende, A; Donders, AR; Evers, AW; Kullberg, BJ; ter Hofstede, HJ; Tromp, M; van den Hoogen, FH; van Middendorp, H; Vogelaar, ML; Vos, FJ, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berende, A | 4 |
| Nieuwenhuis, L | 1 |
| Ter Hofstede, HJM | 2 |
| Vos, FJ | 4 |
| Vogelaar, ML | 3 |
| Tromp, M | 2 |
| van Middendorp, H | 4 |
| Donders, ART | 1 |
| Evers, AWM | 2 |
| Kullberg, BJ | 4 |
| Adang, EMM | 1 |
| Kessels, RPC | 1 |
| ter Hofstede, HJ | 2 |
| Donders, AR | 2 |
| Kessels, RP | 1 |
| Adang, EM | 1 |
| Evers, AW | 2 |
| van den Hoogen, FH | 1 |
| Melia, MT | 1 |
| Auwaerter, PG | 1 |
| Steurer, J | 1 |
| Füessl, HS | 1 |
| Stiefelhagen, P | 1 |
| Donta, ST | 1 |
| Fritzsche, M | 1 |
| Steere, AC | 1 |
| Angelis, SM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Persistent Lyme Empiric Antibiotic Study Europe. A Prospective, Randomised Study Comparing Two Prolonged Oral Antibiotic Strategies After Initial Intravenous Ceftriaxone Therapy for Patients With Symptoms of Proven or Possible Persistent Lyme Disease[NCT01207739] | Phase 4 | 280 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for hydroxychloroquine and Lyme Disease
| Article | Year |
|---|---|
Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; B | 2006 |
5 trials available for hydroxychloroquine and Lyme Disease
| Article | Year |
|---|---|
Cost-effectiveness of longer-term versus shorter-term provision of antibiotics in patients with persistent symptoms attributed to Lyme disease.
Topics: Anti-Bacterial Agents; Ceftriaxone; Clarithromycin; Cost-Benefit Analysis; Double-Blind Method; Doxy | 2018 |
Effect of prolonged antibiotic treatment on cognition in patients with Lyme borreliosis.
Topics: Adult; Anti-Bacterial Agents; Ceftriaxone; Chronic Disease; Clarithromycin; Cognition; Double-Blind | 2019 |
Persistent Lyme Empiric Antibiotic Study Europe (PLEASE)--design of a randomized controlled trial of prolonged antibiotic treatment in patients with persistent symptoms attributed to Lyme borreliosis.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Borrelia burgdorferi; Ceftriaxone; Double-Blind | 2014 |
Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease.
Topics: Adult; Anti-Bacterial Agents; Antimalarials; Clarithromycin; Double-Blind Method; Doxycycline; Drug | 2016 |
[Months of antibiotic therapy in persistent symptoms of Lyme disease without effect].
Topics: Anti-Bacterial Agents; Chronic Disease; Clarithromycin; Dose-Response Relationship, Drug; Doxycyclin | 2016 |
4 other studies available for hydroxychloroquine and Lyme Disease
| Article | Year |
|---|---|
Time for a Different Approach to Lyme Disease and Long-Term Symptoms.
Topics: Anti-Bacterial Agents; Antimalarials; Clarithromycin; Doxycycline; Female; Humans; Hydroxychloroquin | 2016 |
[Do combinations with hydroxychloroquine help?].
Topics: Anti-Bacterial Agents; Antimalarials; Chronic Disease; Doxycycline; Drug Therapy, Combination; Human | 2012 |
Macrolide therapy of chronic Lyme Disease.
Topics: Anti-Bacterial Agents; Borrelia burgdorferi; Clarithromycin; Enzyme Inhibitors; Humans; Hydrogen-Ion | 2003 |
Chronic Lyme borreliosis at the root of multiple sclerosis--is a cure with antibiotics attainable?
Topics: Animals; Anti-Bacterial Agents; Borrelia burgdorferi Group; Chronic Disease; Drug Therapy, Combinati | 2005 |